바로가기 및 건너띄기 링크: 본문 바로가기; 주메뉴 바로가기

제약글로벌정보센터

법령 및 고시

home > 제약글로벌정보센터> 의약품 인허가정보> 법령 및 고시

글자크기

Mirabegron - extended-release tablets 관련 특허분쟁

Mirabegron - extended-release tablets 관련 특허분쟁 : 작성자, 작성일, 조회수, 출처,원문, 정보 제공
작성자	관리자
작성일	2016-10-27	조회수	1,498
국가정보	북 아메리카>미국
출처	국제지재권분쟁정보포털
원문	http://www.ip-navi.or.kr/disputenews/disputenewsIpDetail.navi?news_seq=173776

등록일 : 2016-10-27

Astellas Pharma, Inc./ Astellas Ireland Co Ltd/ Astellas Pharma Global Development, Inc. v. Sandoz, Inc.
발생일자	2016.10.14
사건번호	1:16-cv-00952
법원국가	UNITED STATES OF AMERICA
관할법원명	D.C.Delaware(지방법원)
침해권리	특허
원고명	Astellas Pharma, Inc./ Astellas Ireland Co Ltd/ Astellas Pharma Global Development, Inc. ( Astellas Pharma, Inc./ Astellas Ireland Co Ltd/ Astellas Pharma Global Development, Inc. / 미국 / 외국기업 )
피고명	Sandoz, Inc. ( Sandoz, Inc. / 미국 / 외국기업 )
소송유형	침해금지
분쟁내용	[Astellas Pharma, Inc. et al v. Sandoz, Inc.] 사건번호 1:16-cv-00952에 따르면 원고 Astellas Pharma, Inc./ Astellas Ireland Co Ltd/ Astellas Pharma Global Development, Inc.는 피고 Sandoz, Inc.을(를) 상대로 특허 USRE44872\|US7342117\|US7982049\|US8835474을(를) 침해하였다는 이유로 미국 델라웨어 지방법원에 소를 제기하였다.
분쟁경과	분쟁중
산업분류	화학？바이오 > 의약품
계쟁제품	mirabegron - extended-release tablets, 25 mg and 50 mg dosage strengths, generic version of Myrbetriq？
지재권번호/명칭	USRE44872	Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient
	US7342117	α-form or β-form crystal of acetanilide derivative
	US7982049	α-form or β-form crystal of acetanilide derivative
	US8835474	Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient

이전글 「혁신형 제약기업 인증현황」일부개정
다음글 의약품 재평가 세부 평가기준

<p>등록일 : 2016-10-27</p>
<table class="list_v3" summary="분쟁현황 상세보기()" cellspacing="0" cellpadding="0"><caption>Astellas Pharma, Inc./ Astellas Ireland Co Ltd/ Astellas Pharma Global Development, Inc. v. Sandoz, Inc.</caption><colgroup><col width="20%" /><col width="10%" /><col width="" /></colgroup>
<tbody>
<tr><th scope="row">발생일자</th>
<td colspan="2">2016.10.14</td>
</tr>
<tr><th scope="row">사건번호</th>
<td colspan="2">1:16-cv-00952</td>
</tr>
<tr><th scope="row">법원국가</th>
<td colspan="2">UNITED STATES OF AMERICA</td>
</tr>
<tr><th scope="row">관할법원명</th>
<td colspan="2">D.C.Delaware(지방법원)</td>
</tr>
<tr><th scope="row">침해권리</th>
<td colspan="2">특허</td>
</tr>
<tr><th scope="row">원고명</th>
<td colspan="2">Astellas Pharma, Inc./ Astellas Ireland Co Ltd/ Astellas Pharma Global Development, Inc. ( Astellas Pharma, Inc./ Astellas Ireland Co Ltd/ Astellas Pharma Global Development, Inc. / 미국 / 외국기업 )</td>
</tr>
<tr><th scope="row">피고명</th>
<td colspan="2">Sandoz, Inc. ( Sandoz, Inc. / 미국 / 외국기업 )</td>
</tr>
<tr><th scope="row">소송유형</th>
<td colspan="2">침해금지</td>
</tr>
<tr><th scope="row">분쟁내용</th>
<td colspan="2">[Astellas Pharma, Inc. et al v. Sandoz, Inc.] 사건번호 1:16-cv-00952에 따르면 원고 Astellas Pharma, Inc./ Astellas Ireland Co Ltd/ Astellas Pharma Global Development, Inc.는 피고 Sandoz, Inc.을(를) 상대로 특허 USRE44872|US7342117|US7982049|US8835474을(를) 침해하였다는 이유로 미국 델라웨어 지방법원에 소를 제기하였다.</td>
</tr>
<tr><th scope="row">분쟁경과</th>
<td colspan="2">분쟁중</td>
</tr>
<tr><th scope="row">산업분류</th>
<td colspan="2">화학？바이오 > 의약품</td>
</tr>
<tr><th scope="row">계쟁제품</th>
<td colspan="2">mirabegron - extended-release tablets, 25 mg and 50 mg dosage strengths, generic version of Myrbetriq？</td>
</tr>
<tr><th scope="row">지재권번호/명칭</th>
<td style="width: 10px;"><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/RE44872" target="_blank"><font color="blue"><u>USRE44872 </u></font></a></td>
<td>Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient</td>
</tr>
<tr><th scope="row"> </th>
<td style="width: 10px;"><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/7342117" target="_blank"><font color="blue"><u> US7342117 </u></font></a></td>
<td>α-form or β-form crystal of acetanilide derivative</td>
</tr>
<tr><th scope="row"> </th>
<td style="width: 10px;"><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/7982049" target="_blank"><font color="blue"><u> US7982049 </u></font></a></td>
<td>α-form or β-form crystal of acetanilide derivative</td>
</tr>
<tr><th scope="row"> </th>
<td style="width: 10px;"><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/8835474" target="_blank"><font color="blue"><u> US8835474 </u></font></a></td>
<td>Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient</td>
</tr>
</tbody>
</table>
<p> </p>

<p>등록일 : 2016-10-27</p> <table class="list_v3" summary="분쟁현황 상세보기()" cellspacing="0" cellpadding="0"><caption>Astellas Pharma, Inc./ Astellas Ireland Co Ltd/ Astellas Pharma Global Development, Inc. v. Sandoz, Inc.</caption><colgroup><col width="20%" /><col width="10%" /><col width="" /></colgroup> <tbody> <tr><th scope="row">발생일자</th> <td colspan="2">2016.10.14</td> </tr> <tr><th scope="row">사건번호</th> <td colspan="2">1:16-cv-00952</td> </tr> <tr><th scope="row">법원국가</th> <td colspan="2">UNITED STATES OF AMERICA</td> </tr> <tr><th scope="row">관할법원명</th> <td colspan="2">D.C.Delaware(지방법원)</td> </tr> <tr><th scope="row">침해권리</th> <td colspan="2">특허</td> </tr> <tr><th scope="row">원고명</th> <td colspan="2">Astellas Pharma, Inc./ Astellas Ireland Co Ltd/ Astellas Pharma Global Development, Inc. ( Astellas Pharma, Inc./ Astellas Ireland Co Ltd/ Astellas Pharma Global Development, Inc. / 미국 / 외국기업 )</td> </tr> <tr><th scope="row">피고명</th> <td colspan="2">Sandoz, Inc. ( Sandoz, Inc. / 미국 / 외국기업 )</td> </tr> <tr><th scope="row">소송유형</th> <td colspan="2">침해금지</td> </tr> <tr><th scope="row">분쟁내용</th> <td colspan="2">[Astellas Pharma, Inc. et al v. Sandoz, Inc.] 사건번호 1:16-cv-00952에 따르면 원고 Astellas Pharma, Inc./ Astellas Ireland Co Ltd/ Astellas Pharma Global Development, Inc.는 피고 Sandoz, Inc.을(를) 상대로 특허 USRE44872|US7342117|US7982049|US8835474을(를) 침해하였다는 이유로 미국 델라웨어 지방법원에 소를 제기하였다.</td> </tr> <tr><th scope="row">분쟁경과</th> <td colspan="2">분쟁중</td> </tr> <tr><th scope="row">산업분류</th> <td colspan="2">화학？바이오 > 의약품</td> </tr> <tr><th scope="row">계쟁제품</th> <td colspan="2">mirabegron - extended-release tablets, 25 mg and 50 mg dosage strengths, generic version of Myrbetriq？</td> </tr> <tr><th scope="row">지재권번호/명칭</th> <td style="width: 10px;"><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/RE44872" target="_blank"><font color="blue"><u>USRE44872 </u></font></a></td> <td>Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient</td> </tr> <tr><th scope="row"> </th> <td style="width: 10px;"><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/7342117" target="_blank"><font color="blue"><u> US7342117 </u></font></a></td> <td>α-form or β-form crystal of acetanilide derivative</td> </tr> <tr><th scope="row"> </th> <td style="width: 10px;"><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/7982049" target="_blank"><font color="blue"><u> US7982049 </u></font></a></td> <td>α-form or β-form crystal of acetanilide derivative</td> </tr> <tr><th scope="row"> </th> <td style="width: 10px;"><a href="http://patft.uspto.gov/netacgi/nph-Parser?Sect2=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/search-bool.html&r=1&f=G&l=50&d=PALL&RefSrch=yes&Query=PN/8835474" target="_blank"><font color="blue"><u> US8835474 </u></font></a></td> <td>Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient</td> </tr> </tbody> </table> <p> </p>
소스입니다. Ctrl+C를 눌러 클립보드로 복사하세요